Sujit Sheth
Pediatric Hematology-Oncology · New York, NYNPI 1841263878
Payments from drug & device makers
Across 305 payments — averaging $3419.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Agios Pharmaceuticals, Inc.$326K
- Bristol Myers Squibb$275K
- Vertex$76K
- Terumo BCT, Inc.$74K
- E.r. Squibb & Sons, L.L.C.$68K
- Novartis$54K
- plus $171K from 11 others
What the payments were for
- Consulting fees$224,19262%
- Speaking & faculty fees$61,10417%
- Grants$2,5001%
- Travel & lodging$59,37717%
- Food & beverage$5,9002%
- Education$5,6452%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Agios Pharmaceuticals, Inc. | 134 | $325,827 |
| Bristol Myers Squibb | 57 | $274,872 |
| Vertex | 52 | $75,838 |
| Terumo BCT, Inc. | 5 | $73,966 |
| E.r. Squibb & Sons, L.L.C. | 16 | $67,704 |
| Novartis | 4 | $53,561 |
| Regeneron | 4 | $46,125 |
| Apo-pharma Inc. | 4 | $33,636 |
| La Jolla Pharmaceutical Company | 5 | $32,180 |
| Genetix Biotherapeutics Inc | 2 | $23,500 |
| Chiesi USA, Inc. | 12 | $17,375 |
| Novo Nordisk Health Care AG | 3 | $7,653 |
| Acceleron Pharma, Inc. | 2 | $5,940 |
| Octapharma USA, Inc. | 1 | $2,500 |
| Genentech, Inc. | 1 | $1,539 |
| Mckesson Corporation | 1 | $530 |
| Genentech USA, Inc. | 2 | $350 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,043,097 in reported general payments places this provider in the 90th percentile of 196 pediatric hematology-oncology providers in New York.
See all pediatric hematology-oncology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pediatric hematology-oncology in New York
- Lewis SilvermanNew York$33.2M
- Monica BhatiaNew York$7M
- Francine BleiNew York$5.3M
- John LevineNew York$5.1M
- Jaap Jan BoelensNew York$2.5M
- Matthias KarajannisNew York$2.1M
- Nai-Kong CheungNew York$1.2M
- Stephen GilheeneyNew York$1.1M
- Tanya TrippettNew York$1M
- Christopher ForlenzaNew York$853K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.